Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493169 | PMC |
| http://dx.doi.org/10.25122/jml-2024-1011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pioneers in Dermatology and Venereology: An interview with Professor Sabine Werner.
J Eur Acad Dermatol Venereol
January 2025
Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
Contrasting versions of Medical Police, the forerunner of Public Health, in Edinburgh in the early 19th century.
J Med Biogr
December 2024
Royal College of Surgeons of Edinburgh, Surgeons' Hall Museums, Edinburgh, UK.
Andrew Duncan Senior and John Roberton were medical figures who wrote about Medical Police, the forerunner of Public Health, at the turn of the 18th century in Edinburgh. Duncan was an establishment figure, already a Professor at Edinburgh University Medical School when he began a series of lectures on the legal context of medicine, the first of its kind in the UK. Roberton was a less conventional person whose medical qualifications were dubious but who wrote a textbook on Medial Police, the first in the English language.
View Article and Find Full Text PDFDisentangling Neurodegeneration From Aging in Multiple Sclerosis Using Deep Learning: The Brain-Predicted Disease Duration Gap.
Neurology
November 2024
From the Queen Square Multiple Sclerosis Centre (G.P., F.P., J.C., B.K., O.A.-M., S.A.-A., A. Bianchi, W.J.B., R. Christensen, E.C., S. Collorone, M.A.F., Y.H., A.H., S. Mohamud, R.N., A.T.T., J.W., C.Y., O.C., F.B.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, United Kingdom; MS Center Amsterdam (G.P., H.V., F.B.), Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, the Netherlands; Departments of Advanced Biomedical Sciences and Electrical Engineering and Information Technology (G.P., A. Brunetti, S. Cocozza), University of Naples "Federico II," Italy; Centre for Medical Image Computing (F.P., B.K., F.B.), Department of Medical Physics and Biomedical Engineering, University College London, United Kingdom; E-Health Center (F.P.), Universitat Oberta de Catalunya, Barcelona, Spain; Institute of Neuroradiology (B.B., C.L.), St. Josef Hospital, Ruhr-University Bochum, Germany; Department of Advanced Medical and Surgical Sciences (A. Bisecco, A.G.), University of Campania "Luigi Vanvitelli," Naples, Italy; Translational Imaging in Neurology (ThINK) Basel (A.C., C. Granziera), Department of Biomedical Engineering, Faculty of Medicine, University Hospital Basel, University of Basel; Neurologic Clinic and Policlinic (A.C., C. Granziera, J.K.), MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Switzerland; Department of Neurosciences, Biomedicine and Movement Sciences (M. Calabrese, M. Castellaro), University of Verona; Department of Information Engineering (M. Castellaro), University of Padova; Department of Medicine, Surgery and Neuroscience (R. Cortese, N.D.S.), University of Siena, Italy; Department of Neurology (C.E., D.P.), Medical University of Graz, Austria; Neuroimaging Research Unit (M.F., M.A.R., P.V.), Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Neurology Unit, Neurorehabilitation Unit, Neurophysiology Service, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University (M.F., M.A.R., P.V.), Milan; Department of Neurosciences (C. Gasperini, S.R.), San Camillo-Forlanini Hospital, Rome, Italy; Department of Neurology (G.G.-E., S.G.), Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Germany; Department of Neurology (H.F.F.H., E.A.H., G.O.N.), Oslo University Hospital; Institute of Clinical Medicine (H.F.F.H., E.A.H., G.O.N.), and Department of Psychology (E.A.H.), University of Oslo, Norway; Neuroimmunology and Multiple Sclerosis Unit Laboratory of Advanced Imaging in Neuroimmunological Diseases (ImaginEM) (S.L., E.M.-H.), Hospital Clinic Barcelona, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Su, Barcelona, Spain; Department of Neurology (C.L.), St. Josef Hospital, Ruhr-University Bochum, Germany; Nuffield Department of Clinical Neurosciences (S. Messina, J.P.), University of Oxford, United Kingdom; Department of Molecular Medicine and Medical Biotechnology (M.M.), and Department of Neurosciences and Reproductive and Odontostomatological Sciences (M.P.), University of Naples "Federico II"; Department of Human Neurosciences (M.P.), Sapienza University of Rome, Italy; Section of Neuroradiology (A.R.), Department of Radiology, and Centre d'Esclerosi Múltiple de Catalunya (Cemcat) (J.S.-G.), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; MS Center Amsterdam (E.M.M.S.), Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, the Netherlands; Department of Neurology and Center of Clinical Neuroscience (T.U.), and Department of Radiology (M.V.), First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic; MS Center Amsterdam (M.M.S.), Anatomy and Neurosciences, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, the Netherlands; Centre for Medical Image Computing (J.H.C.), Department of Computer Science, and Dementia Research Centre (J.H.C., F.B.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.
Background And Objectives: Disentangling brain aging from disease-related neurodegeneration in patients with multiple sclerosis (PwMS) is increasingly topical. The brain-age paradigm offers a window into this problem but may miss disease-specific effects. In this study, we investigated whether a disease-specific model might complement the brain-age gap (BAG) by capturing aspects unique to MS.
View Article and Find Full Text PDFVenetoclax Combined With FLAG-IDA in Refractory or Relapsed Acute Myeloid Leukemia.
Eur J Haematol
January 2025
University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany.
Introduction: The prognosis of patients with refractory or relapsed AML (R/R-AML) is very limited. To (re)achieve complete remission, there has recently been increasing evidence that the combination of venetoclax (VEN) with chemotherapy is associated with improved outcomes.
Patients And Methods: Our retrospective, single-center study of 53 R/R-AML patients with a median follow-up time of 11.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!